tetano
Editor, Senior Moderator
Expert Rev Vaccines. 2015 Apr 11:1-11. [Epub ahead of print]
[h=1]Live attenuated influenza vaccine tetravalent: a clinical review.[/h] Bandell AR[SUP]1[/SUP], Sim?es EA.
[h=3]Author information[/h]
[h=3]Abstract[/h] Live attenuated influenza vaccine (LAIV) has been available as a trivalent formulation in the EU since 2012. Influenza B strains from two lineages have co-circulated outside Asia in Europe, Israel and North America since the early 2000s. The trivalent vaccine contained a single influenza B lineage virus chosen primarily on the basis of the previous year's circulating lineage. Failure to align the vaccine virus with the circulating virus leaves even vaccinated patients, particularly children, at risk for infection with B viruses from the other lineage. Recently, a tetravalent formulation was approved and use will begin during the 2014-2015 influenza season. Approval of LAIV Tetra was based on the established efficacy and safety of trivalent LAIV and studies demonstrating similar immunogenicity between the trivalent and tetravalent vaccines. Addition of a fourth strain to the vaccine will address the issue of co-circulation of influenza B viruses and provide a broader range of protection.
[h=4]KEYWORDS:[/h] intranasal influenza vaccine; live attenuated influenza vaccine; tetra; tetravalent
PMID: 25864428 [PubMed - as supplied by publisher]
[h=1]Live attenuated influenza vaccine tetravalent: a clinical review.[/h] Bandell AR[SUP]1[/SUP], Sim?es EA.
[h=3]Author information[/h]
[h=3]Abstract[/h] Live attenuated influenza vaccine (LAIV) has been available as a trivalent formulation in the EU since 2012. Influenza B strains from two lineages have co-circulated outside Asia in Europe, Israel and North America since the early 2000s. The trivalent vaccine contained a single influenza B lineage virus chosen primarily on the basis of the previous year's circulating lineage. Failure to align the vaccine virus with the circulating virus leaves even vaccinated patients, particularly children, at risk for infection with B viruses from the other lineage. Recently, a tetravalent formulation was approved and use will begin during the 2014-2015 influenza season. Approval of LAIV Tetra was based on the established efficacy and safety of trivalent LAIV and studies demonstrating similar immunogenicity between the trivalent and tetravalent vaccines. Addition of a fourth strain to the vaccine will address the issue of co-circulation of influenza B viruses and provide a broader range of protection.
[h=4]KEYWORDS:[/h] intranasal influenza vaccine; live attenuated influenza vaccine; tetra; tetravalent
PMID: 25864428 [PubMed - as supplied by publisher]